vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and SITIME Corp (SITM). Click either name above to swap in a different company.
SITIME Corp is the larger business by last-quarter revenue ($113.3M vs $57.3M, roughly 2.0× RHYTHM PHARMACEUTICALS, INC.). SITIME Corp runs the higher net margin — 8.1% vs -83.0%, a 91.1% gap on every dollar of revenue. On growth, SITIME Corp posted the faster year-over-year revenue change (66.3% vs 36.9%). Over the past eight quarters, SITIME Corp's revenue compounded faster (85.2% CAGR vs 48.5%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
RYTM vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $113.3M |
| Net Profit | $-47.5M | $9.2M |
| Gross Margin | 91.6% | 56.4% |
| Operating Margin | -82.2% | 1.6% |
| Net Margin | -83.0% | 8.1% |
| Revenue YoY | 36.9% | 66.3% |
| Net Profit YoY | -9.6% | 148.7% |
| EPS (diluted) | $-0.73 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $113.3M | ||
| Q3 25 | $51.3M | $83.6M | ||
| Q2 25 | $48.5M | $69.5M | ||
| Q1 25 | $32.7M | $60.3M | ||
| Q4 24 | $41.8M | $68.1M | ||
| Q3 24 | $33.3M | $57.7M | ||
| Q2 24 | $29.1M | $43.9M | ||
| Q1 24 | $26.0M | $33.0M |
| Q4 25 | $-47.5M | $9.2M | ||
| Q3 25 | $-52.9M | $-8.0M | ||
| Q2 25 | $-46.6M | $-20.2M | ||
| Q1 25 | $-49.5M | $-23.9M | ||
| Q4 24 | $-43.3M | $-18.8M | ||
| Q3 24 | $-43.6M | $-19.3M | ||
| Q2 24 | $-32.3M | $-26.8M | ||
| Q1 24 | $-141.4M | $-28.7M |
| Q4 25 | 91.6% | 56.4% | ||
| Q3 25 | 89.3% | 53.5% | ||
| Q2 25 | 88.6% | 51.9% | ||
| Q1 25 | 88.8% | 50.3% | ||
| Q4 24 | 90.9% | 52.6% | ||
| Q3 24 | 88.5% | 51.1% | ||
| Q2 24 | 89.9% | 49.1% | ||
| Q1 24 | 89.2% | 53.5% |
| Q4 25 | -82.2% | 1.6% | ||
| Q3 25 | -102.6% | -19.2% | ||
| Q2 25 | -93.4% | -35.4% | ||
| Q1 25 | -143.7% | -46.6% | ||
| Q4 24 | -98.6% | -33.8% | ||
| Q3 24 | -132.0% | -43.1% | ||
| Q2 24 | -139.2% | -73.7% | ||
| Q1 24 | -538.7% | -106.1% |
| Q4 25 | -83.0% | 8.1% | ||
| Q3 25 | -103.1% | -9.6% | ||
| Q2 25 | -96.1% | -29.0% | ||
| Q1 25 | -151.4% | -39.6% | ||
| Q4 24 | -103.6% | -27.6% | ||
| Q3 24 | -131.2% | -33.5% | ||
| Q2 24 | -110.9% | -61.0% | ||
| Q1 24 | -544.4% | -86.9% |
| Q4 25 | $-0.73 | $0.44 | ||
| Q3 25 | $-0.82 | $-0.31 | ||
| Q2 25 | $-0.75 | $-0.84 | ||
| Q1 25 | $-0.81 | $-1.01 | ||
| Q4 24 | $-0.71 | $-0.80 | ||
| Q3 24 | $-0.73 | $-0.83 | ||
| Q2 24 | $-0.55 | $-1.16 | ||
| Q1 24 | $-2.35 | $-1.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $1.2B |
| Total Assets | $480.2M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | — | ||
| Q3 25 | $416.1M | — | ||
| Q2 25 | $291.0M | — | ||
| Q1 25 | $314.5M | — | ||
| Q4 24 | $320.6M | — | ||
| Q3 24 | $298.4M | — | ||
| Q2 24 | $319.1M | — | ||
| Q1 24 | $201.2M | — |
| Q4 25 | $139.1M | $1.2B | ||
| Q3 25 | $148.8M | $1.1B | ||
| Q2 25 | $-11.9M | $1.1B | ||
| Q1 25 | $18.9M | $692.5M | ||
| Q4 24 | $21.7M | $699.7M | ||
| Q3 24 | $11.2M | $696.2M | ||
| Q2 24 | $39.3M | $692.5M | ||
| Q1 24 | $61.6M | $696.2M |
| Q4 25 | $480.2M | $1.3B | ||
| Q3 25 | $506.9M | $1.3B | ||
| Q2 25 | $372.7M | $1.3B | ||
| Q1 25 | $386.7M | $872.1M | ||
| Q4 24 | $392.3M | $885.0M | ||
| Q3 24 | $363.6M | $877.9M | ||
| Q2 24 | $381.8M | $878.6M | ||
| Q1 24 | $258.7M | $942.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $25.4M |
| Free Cash FlowOCF − Capex | — | $13.0M |
| FCF MarginFCF / Revenue | — | 11.5% |
| Capex IntensityCapex / Revenue | — | 10.9% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | — | $35.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $25.4M | ||
| Q3 25 | $-26.6M | $31.4M | ||
| Q2 25 | $-23.3M | $15.3M | ||
| Q1 25 | $-40.4M | $15.0M | ||
| Q4 24 | $-18.8M | $13.5M | ||
| Q3 24 | $-25.2M | $8.2M | ||
| Q2 24 | $-29.1M | $-181.0K | ||
| Q1 24 | $-40.7M | $1.7M |
| Q4 25 | — | $13.0M | ||
| Q3 25 | — | $26.3M | ||
| Q2 25 | — | $-2.9M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $-2.4M | ||
| Q3 24 | — | $-6.7M | ||
| Q2 24 | — | $-2.7M | ||
| Q1 24 | — | $-1.2M |
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 31.5% | ||
| Q2 25 | — | -4.2% | ||
| Q1 25 | — | -2.1% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | — | -11.6% | ||
| Q2 24 | — | -6.3% | ||
| Q1 24 | — | -3.6% |
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 26.2% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 23.3% | ||
| Q3 24 | — | 25.7% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | — | 8.8% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
